Raj Reddy
Chief Executive Officer Canary Cure
Raj Reddy is a biotechnology pioneer and the President and CEO of Canary Cure Therapeutics. He has over 10 years of experience in leading and scaling biotech ventures and specializes in the endocannabinoid system’s role in metabolic health. Raj brings deep expertise in pharmacology and medicinal chemistry to the company’s groundbreaking work. As the inventor on over 20 patents in genetics and RNA therapy, Raj leads Canary?s development of first-in-class siRNA therapeutics that transform white adipose tissue into energy-burning powerhouses. His flagship innovation, CCT-217, demonstrates unprecedented outcomes in pre-clinical models, achieving 26% weight loss while increasing lean muscle mass by 25%. Raj’s strategic vision combines cutting-edge RNA technology with AI-enhanced personalized approaches to revolutionize treatment paradigms. His previous leadership over a $500 million portfolio has honed his expertise in strategic management and market access. Driven by the transformative potential of genetic medicine, Raj is committed to unlocking new frontiers in precision medicine that enable earlier detection and more effective disease treatment through targeted genetic mechanisms.
Seminars
This intensive workshop explores the limitations of monolithic obesity treatments by shifting the focus from simple appetite suppression to the functional genomics and proteomics of energy expenditure. By examining the mechanistic drivers of thermogenesis and the evolving role of the adipocyte, participants will discover how to bypass the limitations of current standards of care and address critical clinical challenges, such as the deterioration of metabolic health and muscle atrophy associated with rapid weight loss.
This session will cover:
- Balancing the Two Levers of Weight Loss & Comparative Bioenergetics: Shifting the therapeutic paradigm from solely restricting energy intake to safely maximizing energy expenditure through novel thermogenic pathways.
- Overcoming the "Lean-Mass Trap" and the Muscle Problem: Addressing the critical challenge of muscle atrophy by prioritizing the preservation and enhancement of lean muscle mass alongside fat-selective reduction.
- Targeting the Adipocyte, Beiging, & UCP1-Independent Thermogenesis: Decoding phenotypic switching and alternative cellular energy expenditure mechanisms beyond traditional UCP1 pathways.
- Leveraging Functional Genomics, Proteomics, & Batokines: Utilizing high-resolution molecular data and batokine biomarker read-outs to identify novel targets, culminating in a Case Study on translating these insights into highly targeted therapeutic assets.
• Introduction to the Modular Next Gen Hyper15™ Delivery Platform, the first technology capable of bypassing the endosome to successfully deliver dual siRNA payloads directly to adipose tissue. This breakthrough enables precise genetic silencing within the fat cell itself, treating the tissue as a metabolic organ rather than just a storage depot.
Differentiating CCT-217 from standard-of-care incretins by moving “Beyond Appetite.” We present data showing how silencing adipose-specific genes at their mitochondrial receptors unlocks thermogenic energy expenditure and lipolysis, driving weight loss through metabolic upregulation rather than caloric restriction/starvation physiology.
A deep dive into the compositional and commercial advantage of CCT-217. We demonstrate how CCT-217 delivers Selective Fat Mass reduction and Muscle Enhancement—avoiding the sarcopenic trap of GLP-1s—while offering an Ultra-Long Duration dosing profile (6+ months) that redefines treatment adherence
